Stereotactic Body Radiation for Consolidation After Standard Chemoradiation for Stage 3 Lung Cancer
This protocol will investigate the potential role of SBRT for patients with stage 3 NSCLC.
Eligible patients will first have received standard 50.4 Gy chemoradiation. Patients
entering the study will have the opportunity to receive SBRT as a noninvasive option as
compared to surgical resection. For patients who are not surgical candidates, SBRT after
50.4 Gy chemoradiation represents a technique of radiation consolidation that may be more
effective and less toxic than standard conventional fractionated radiation
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
early and intermediate toxicity
Any toxicity related to the radiation treatment will be scored and graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0
3 months
Yes
United States: Food and Drug Administration
BrUOG 259
NCT01656460
April 2012
October 2013
Name | Location |
---|---|
Rhode Island Hospital | Providence, Rhode Island 02903 |
Memorial Hospital of Rhode Island | Pawtucket, Rhode Island 02860 |